Premium
AMIODARONE INDUCED CORNEA VERTICILLATA
Author(s) -
NIELSEN CLAUS EGE,
ANDREASEN FREDERIK,
BJERREGAARD PREBEN
Publication year - 1983
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.1983.tb01447.x
Subject(s) - amiodarone , cornea , medicine , ophthalmology , tears , visual acuity , fundus (uterus) , anesthesia , surgery , atrial fibrillation
Among 30 patients (17 men, 46–76 years and 13 women, 15–70 years), treated with the antiarrhythmic drug amiodarone, 21 patients (11 men and 10 women) developed bilateral cornea verticillata. Total doses up to 494 g had been given and the duration of therapy was up to 113 weeks. In 14 patients samples of 50 μl tear fluid were analyzed for aminodarone. No amiodarone was present in the tears at low serum concentrations but a rapid increase in tear concentrations was seen at serum values above 1.2 μg/ml ( P < 0.001). The grade of cornea verticillata was significantly correlated to total dose as well as to duration of treatment ( P ≦ 0.001). On the day of examination at the eye clinic there was no significant correlation between se‐amiodarone, tear‐amiodarone concentration and the grade of cornea verticillata. One patient complained of coloured haloes. None had decreased visual acuity, fundus changes, cataract, exophthalmus, increased intraocular pressure, abnormal colour vision, or abnormal central corneal thickness, which could be attributed to the treatment of amiodarone.